NCT06785714Completed
Colorectal Cancer Screening in Xinxiang City
Source: ClinicalTrials.gov · Last updated 21 Jan 2025
Brief summary (registry, in English)
The primary objective of this study is to evaluate the sensitivity of the fecal protein dual-index test reagent for the detection of colorectal cancer (CRC).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 25000 (actual)
- First submitted
- 15 Jan 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 15 Jan 2025
- Lead sponsor
- The First Affiliated Hospital of Xinxiang Medical College
- Diseases
- Colorectal cancer
- NCT number
- NCT06785714
What you commit to
- Study type: Observational
- Participants enrolled: 25000
- From 1 Sept 2024 to the primary completion date, 15 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of colorectal cancer
Other illness
- Patients who have been confirmed to have other malignant neoplastic diseases of the digestive system
- Patients with severe heart, brain, lung disease or liver and kidney dysfunction or insufficiency
- Those with severe mental disorders and language communication disorders
- History of contraindications to colonoscopy
Other
- Pregnant women
Who the study is looking for
- Subjects aged 45-74 years at time of consent
- Have not had gastrointestinal resection
Age in the registry: 45 years to 74 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Xinxiang Medical University Coordinator of this site? Confirm its status | Xinxiang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.